Maintaining weight loss after GLP1 treatment requires more than medication alone
Most incretin weight-loss therapies are injected subcutaneously, but oral semaglutide is already licensed in the UK for T2DM as Rybelsus, while its manufacturer Novo Nordisk has published positive phase III results (OASIS-4, NCT05564117) for its 25mg semaglutide pill for weight loss 6
primary-cta Considerations for Patients If you're exploring options for improving metabolic health, you may be wondering when these kinds of innovations will be available
Thats what were here for at Josie
Why Retatrutide is Exciting : Triple Mechanism = Broader Impact: Targets fat loss, insulin sensitivity, and energy balance simultaneously Once-Weekly Dosing: High compliance, low friction Backed by Data: Clinically validated, outperforming single and dual agonists in key metrics Ideal for Advanced Protocols: Perfect for those looking for the best potential results Outperforms Semaglutide & Tirzepatide for total weight lost in trials Available in Canada with fast domestic shipping Most common side effects: Nausea, diarrhea & constipation Side effects are dose dependent and typically subside the longer the drug is used You can check out the full guide on managing Retatrutide side effects by clicking on the link
Individuals with associated conditions like type 2 diabetes, high blood pressure, or high cholesterol may particularly benefit
